Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 2/20 | 0.75 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.75 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.75 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14866129 | 0.87 | PRKD3 (0.58) | PRKD3PRKD1PRKD2ALDH1A1CYP1A2 | |
| SCHEMBL4511350 | 0.86 | PRKD3 (0.74) | PRKD3PRKD1PRKD2HRH3ALDH1A1 | |
| SCHEMBL4511344 | 0.86 | PRKD3 (0.74) | PRKD3PRKD1PRKD2HRH3ALDH1A1 | |
| SCHEMBL4511341 | 0.86 | PRKD3 (0.74) | PRKD3PRKD1PRKD2HRH3ALDH1A1 | |
| SCHEMBL4514713 | 0.86 | PRKD3 (1.00) | PRKD3PRKD1PRKD2 | |
| SCHEMBL4514725 | 0.86 | PRKD3 (1.00) | PRKD3PRKD1PRKD2 | |
| SCHEMBL4514722 | 0.86 | PRKD3 (1.00) | PRKD3PRKD1PRKD2 | |
| SCHEMBL4512516 | 0.85 | PRKD3 (0.72) | PRKD3PRKD1PRKD2HRH3CYP3A4 | |
| SCHEMBL4512527 | 0.85 | PRKD3 (0.72) | PRKD3PRKD1PRKD2HRH3CYP3A4 | |
| SCHEMBL4523068 | 0.85 | PRKD3 (0.72) | PRKD3PRKD1PRKD2HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340491-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC AND CARDIOVASCULAR DISEASES | UNIVERSITY OF ROCHESTER | 2023-10-26 | — | — | US | disclosed |
| US-20160354372-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | THE J. DAVID GLADSTONE INSTITUTES | 2016-12-08 | — | — | US | disclosed |
| US-9359445-B2 | Compositions and methods for treating neurological disorders | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-06-07 | — | — | US | disclosed |
| US-20130095113-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354372-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | PKD2, PKD1, CKMT1A; CKMT1B | PRKD3 74/4885PRKD1 62/4885PRKD2 50/4885 |
| US-20230340491-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC AND CARDIOVASCULAR DISEASES | LIPC, FABP1, GOT2 | PRKD3 1685/4885PRKD1 2799/4885PRKD2 2848/4885 |
| US-20130095113-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | PKD2, PKD1, CKMT1A; CKMT1B | PRKD3 74/4885PRKD1 62/4885PRKD2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.